Rethinking the Standard for Ductal Carcinoma In Situ Treatment

Affiliations

Editorial

Laura Esserman et al. JAMA Oncol. 2015 Oct.

. 2015 Oct;1(7):881-3.

doi: 10.1001/jamaoncol.2015.2607.

No abstract available

Comment in

Pathologic Abnormalities Behind Ductal Carcinoma In Situ Terminology.
Foucar E. Foucar E. JAMA Oncol. 2016 Mar;2(3):394-5. doi: 10.1001/jamaoncol.2015.4843. JAMA Oncol. 2016. PMID: 26967175 No abstract available.
Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ.
Espina V, Williams JP, Liotta LA. Espina V, et al. JAMA Oncol. 2016 Mar;2(3):395. doi: 10.1001/jamaoncol.2015.4846. JAMA Oncol. 2016. PMID: 26967176 No abstract available.
Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply.
Esserman L, Yau C. Esserman L, et al. JAMA Oncol. 2016 Mar;2(3):395-6. doi: 10.1001/jamaoncol.2015.4840. JAMA Oncol. 2016. PMID: 26967177 No abstract available.

Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.
Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Narod SA, et al. JAMA Oncol. 2015 Oct;1(7):888-96. doi: 10.1001/jamaoncol.2015.2510. JAMA Oncol. 2015. PMID: 26291673